A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

This Phase 3 study tests ersodetug, a new drug designed to block excess insulin production in people with a rare condition called tumor hyperinsulinism — where a neuroendocrine tumor (a slow-growing cancer of hormone-producing cells) causes the body to overproduce insulin, leading to dangerously low blood sugar levels that cannot be controlled by standard means. **You may be eligible if:** - You are 18 or older - You have a confirmed neuroendocrine tumor that is causing dangerously low blood sugar (hypoglycemia) due to excess insulin or insulin-like factors - Standard treatments to control your blood sugar have not worked - You are currently requiring intravenous glucose or nutrition support for at least 7 days to manage your blood sugar - Your case has been reviewed by a multidisciplinary team including an oncologist **You may NOT be eligible if:** - Your hypoglycemia is caused by something other than a neuroendocrine tumor - You have not yet tried standard anti-hypoglycemic therapies - You are not currently dependent on IV glucose or nutritional support - You are pregnant or breastfeeding - You have serious other conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.